Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure.

Li HK, Chen FC, Rea RF, Asirvatham SJ, Powell BD, Friedman PA, Shen WK, Brady PA, Bradley DJ, Lee HC, Hodge DO, Slusser JP, Hayes DL, Cha YM.

Pacing Clin Electrophysiol. 2011 Jul;34(7):868-74. doi: 10.1111/j.1540-8159.2011.03049.x. Epub 2011 Mar 16.

PMID:
21410724
2.

Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.

Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA.

J Am Coll Cardiol. 2010 May 25;55(21):2376-82. doi: 10.1016/j.jacc.2009.12.056.

3.

Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios.

Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N, Wall TS, Daccarett M.

Pacing Clin Electrophysiol. 2010 Apr;33(4):400-6. doi: 10.1111/j.1540-8159.2010.02703.x. Epub 2010 Feb 18.

PMID:
20180915
4.
5.
6.

The impact of pharmacist-managed oral anticoagulation therapy in older veterans.

Poon IO, Lal L, Brown EN, Braun UK.

J Clin Pharm Ther. 2007 Feb;32(1):21-9.

PMID:
17286786
7.

The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.

Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H, Goldman S.

Pacing Clin Electrophysiol. 2010 Apr;33(4):385-8. doi: 10.1111/j.1540-8159.2009.02674.x. Epub 2010 Jan 4.

PMID:
20059711
8.

Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.

Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY.

Circulation. 2012 Mar 20;125(11):1414-23. doi: 10.1161/CIRCULATIONAHA.111.059188. Epub 2012 Feb 8.

9.
10.

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators.

J Thromb Haemost. 2006 Jun;4(6):1246-52.

11.

Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial.

Schulman S, Healey JS, Douketis JD, Delaney J, Morillo CA.

Thromb Res. 2014 Oct;134(4):814-8. doi: 10.1016/j.thromres.2014.07.028. Epub 2014 Aug 1.

PMID:
25127655
12.

Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.

Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD.

Am Heart J. 2009 Aug;158(2):252-6. doi: 10.1016/j.ahj.2009.06.005.

PMID:
19619702
13.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
14.
15.

Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation.

Chen HC, Chen YL, Guo BF, Tsai TH, Chang JP, Pan KL, Lin YS, Chen MC.

Can J Cardiol. 2013 Sep;29(9):1110-7. doi: 10.1016/j.cjca.2012.12.014. Epub 2013 Mar 6.

PMID:
23474139
16.

Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy.

Giudici MC, Paul DL, Bontu P, Barold SS.

Pacing Clin Electrophysiol. 2004 Mar;27(3):358-60.

PMID:
15009863
17.

Preprocedural therapeutic international normalized ratio influence on bleeding complications in atrial fibrillation ablation with continued anticoagulation with warfarin.

Hayashi T, Kumagai K, Naito S, Goto K, Kaseno K, Ohshima S, Hachiya H, Hirao K, Isobe M.

Circ J. 2013;77(2):338-44. Epub 2012 Oct 20.

18.

Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.

DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, DeCaro M, Ruggiero N, Singhal S, Greenspon A.

Pharmacotherapy. 2007 May;27(5):691-6.

PMID:
17461704
19.

Anticoagulation management in the perioperative phase of implantable cardioverter defibrillator implantation.

Yokoshiki H, Mitsuyama H, Watanabe M, Mizukami K, Matsui Y, Tsutsui H.

Circ J. 2013;77(8):2003-8. Epub 2013 May 15.

20.

[Major closed-space bleeding in patients on anticoagulation with acenocoumarol (TAO) or non-fractionned heparin(HS): a case-control study].

Martínez Lacasa J, Juan N, Juliá J, Rodríguez-Carballeira M, de Diego I, Soto R, Garau J.

An Med Interna. 2008 Jan;25(1):9-14. Spanish.

PMID:
18377188

Supplemental Content

Support Center